Clinical Trial Update: Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pre-emptive daratumumab therapy for minimal residual disease reappearance or biochemical relapse in multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: Polish Myeloma Consortium | Conditions: Multiple Myeloma | Phase 2 | Status: UNKNOWN